Muscular Dystrophy Therapy Cleared By FDA For This Bioscience Company

FDA Greenlights Solid Biosciences' SGT-003 for Duchenne Muscular Dystrophy: A Breakthrough in Gene Therapy.

In a significant leap forward for gene therapy, the U.S. Food and Drug Administration (FDA) has cleared Solid Biosciences' Investigational New Drug (IND) application for SGT-003. This experimental gene therapy candidate has been developed for the treatment of Duchenne Muscular Dystrophy (DMD), a debilitating genetic disorder that primarily affects boys.

…